Go Ahead Sunshine

Go Ahead Sunshine (Beijing) Technology is a clinical-stage biotechnology company and a subsidiary of 3SBio Inc., specializing in the development of therapeutic monoclonal antibodies. The company focuses on addressing unmet medical needs in autoimmune and inflammatory diseases through its innovative pipeline of biologics. Its lead candidate, SSGJ-608, is an anti-IL-17A antibody currently in Phase 3 clinical trials for the treatment of plaque psoriasis. Other significant programs include SSGJ-611, an anti-IL-4Rα antibody for atopic dermatitis, and SSGJ-610, an anti-IL-5 antibody for asthma. By leveraging the extensive R&D and manufacturing infrastructure of the 3SBio group, Go Ahead Sunshine aims to provide advanced treatment options for patients with chronic inflammatory conditions.